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Objective. To assess demographic, socioeconomic and behavioural correlates of HPV vaccination of preadoles-
cent girls in a publicly funded, school-based vaccination programme.
Methods. Data for all Norwegian girls born 1997–1999, eligible for routine school-based HPV vaccination in
2009–2011 (n = 90,842), and their registered mother and father, were merged from national registries. Corre-
lates of girl vaccination status were analysed by unadjusted and multivariable logistic regression.
Results. In total, 78.2% of the girls received the ﬁrst dose of the HPV vaccine, 74.6% received three doses, and
94.8% received the MMR vaccine. Correlates associated with initiation of HPV vaccination included parental age,
income and education, maternal occupational status and cervical screening attendance, and girl receipt of the
MMR vaccine. Rates of completion of HPV vaccination among initiators were high, and disparities in completion
were negligible. Maternal and paternal correlates of daughter HPV vaccination status were similar.
Conclusions. Routine school-based vaccination generally provides equitable delivery, yet some disparities
exist. Information campaigns designed to reach the sub-groups with relatively low vaccine uptake could reduce
disparities. In none of the sub-groups investigated did uptake of the HPV vaccine approach that of theMMR vac-
cine, further demonstrating a general potential for improvement in HPV vaccine uptake.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Human papillomavirus (HPV) can cause cervical cancer (Bosch et al.,
2002) as well as other cancer forms (zur Hausen, 2009) and genital
warts (Aubin et al., 2008). Vaccination against HPV types 6, 11, 16 and
18, which causemost cervical cancers and genital warts, has been avail-
able since 2006. The HPV vaccine has been shown to be generally safe
(Arnheim-Dahlstrom et al., 2013; Slade et al., 2009) and effective
(Baandrup et al., 2013; Leval et al., 2013; Paavonen et al., 2009; Villa
et al., 2007), but the uptake (i.e. the proportion vaccinated in the
targeted population) is low in many countries that have included the
HPV vaccine in their national immunisation programme (Markowitz
et al., 2012).
The correlates of HPV vaccine uptake may differ between vaccination
settings. Opportunistic uptake of the HPV vaccine is strongly associatedancer Registry of Norway, P.O.
o (B.T. Hansen),
ly.burger@medisin.uio.no
. This is an open access article underwith high socioeconomic status (Leval et al., 2013). Socioeconomic status,
ethnicity, previous uptake of other childhood vaccines, maternal age and
maternal screening attendancemay also be associatedwith catch-up vac-
cination of adolescent girls and young women (Poole et al., 2012; Rondy
et al., 2010; Steens et al., 2013). Few large studies have addressed poten-
tial disparities in school-based routine HPV vaccination of preadolescent
girls (Fisher et al., 2013). This vaccinationdelivery approach is particularly
appropriate because preadolescent girls are the primary target for most
HPV vaccination programmes (Markowitz et al., 2012), as vaccine efﬁcacy
is highest among young individuals naive to the HPV vaccine types (Villa
et al., 2007). Moreover, a school-based setting typically achieves the
highest uptake (Hofstetter andRosenthal, 2014) andmay reduce inequal-
ities in uptake (Poole et al., 2012), although some studies indicate that
disparities related to socioeconomic status, ethnicity and other demo-
graphic characteristics may still exist (Fisher et al., 2014; Ogilvie et al.,
2010; Sinka et al., 2014). Additional studies are needed to assess the per-
formance of HPV vaccination in this setting, and potentially, to guide
strategies for improving HPV vaccine uptake.
By merging high-quality individual data frommultiple national regis-
tries, we aim to investigate demographic, socioeconomic and behavioural
correlates of routine school-based HPV vaccination of preadolescent girls
in Norway. Since involvement in child health-related decision makingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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gate maternal and paternal characteristics separately.
Methods
Vaccination setting
The Norwegian childhood vaccination programme (Trogstad et al., 2012) is
administered by the municipality health services, who are obliged by law to
provide the included vaccines to all children living in Norway. HPV vaccination
was included in the programme in 2009. Girls born in 1997 were the ﬁrst eligi-
ble birth cohort. Three doses of the HPV vaccine is offered free of charge at
school to girls in the seventh grade. The vaccine is usually given at months 0,
2 and 6 by the school nurse during school hours. Among other vaccines, the
childhood immunisation programme also offers vaccination against MMR
(measles, mumps and rubella combined) in the sixth grade. Vaccination is op-
tional, and the vaccinee and their parents/guardians have to consent to vaccina-
tion.Written consent is not required, but is encouraged for vaccination of school
children. The Norwegian Institute of Public Health has issuedHPV vaccine infor-
mation letters and consent forms in several languages.
Study population
Girls who were born in 1997, 1998 or 1999, and who were resident in
Norway during the entire school-year they were offered the HPV vaccine
through the programme, were eligible for this study. All Norwegian citizens
have a unique personal identiﬁcation number (PIN), which is used in registries.Fig. 1. The study populations for analyses ofThe National registry contains the PINs for every individual who is or has been
resident in Norway. We used the National registry (October 2013 version) to
identify all females born between 01.01.1997 and 31.12.1999 (n = 97,269).
To avoid inclusion of girls who were not or may not have been offered the
HPV vaccine, we excluded a total of 6427 girls based on dates of death, emigra-
tion, immigration, or registry irregularities, resulting in 90,842 girls meeting the
inclusion criteria. Through the National registry, a mother was identiﬁed for
90,540 eligible girls, and a father was identiﬁed for 88,565 eligible girls. These
girl-mother and girl-father pairs were included in the analyses of initiation of
HPV vaccination. For the analyses of completion of HPV vaccination, we exclud-
ed all girls who did not initiate vaccination, resulting in samples of 70,870 and
69,306 girls for the analyses addressing associationswithmaternal and paternal
characteristics, respectively (Fig. 1).
Registry data
The PIN was used to obtain and to merge individual data from various reg-
istries. To ensure data protection, PINs were managed by authorized registry
personnel only, and were replaced by running numbers before data was made
available for analyses.
Girl vaccination statuswas obtained from theNorwegian immunisation reg-
istry (SYSVAK), from which we requested all dates of HPV and MMR vaccina-
tions. Age and region of residence in the year of scheduled HPV vaccination
was obtained from the National registry. For each mother and father, we re-
quested the following data from Statistics Norway, referring to the year of
scheduled HPV vaccination of the daughter: marital status, education, total in-
come (the sumof income fromwork, properties, taxable and tax-free transfers),HPV vaccination in Norway 2009–2011.
Table 1
Odds ratiosa for initiation and completion of routine HPV vaccination among 12–13 year old girls in Norway 2009–2011 by mother and daughter characteristics.
Initiation Completion among initiators
Nb % initiated Unadjusted OR
(99% CI)
AdjustedcOR
(99% CI)
Nb % completed Unadjusted OR
(99% CI)
AdjustedcOR
(99% CI)
Mother's age
b35 9854 80.0 1.06 (0.99,1.14) 1.16 (1.07,1.26) 7888 95.0 0.89 (0.77,1.04)
35–39 26,012 79.8 1.05 (0.99,1.10) 1.09 (1.03,1.15) 20,767 95.0 0.89 (0.80,1.00)
40–44 32,872 79.1 1.00 (reference) 1.00 (reference) 25,995 95.5 1.00 (reference)
45–49 16,993 75.5 0.82 (0.77,0.86) 0.80 (0.76,0.85) 12,831 95.4 0.98 (0.86,1.12)
N=50 4809 70.5 0.63 (0.58,0.69) 0.64 (0.59,0.71) 3389 95.6 1.03 (0.82,1.30)
Mother's marital status
Unmarried 18,956 79.3 1.08 (1.02,1.14) 1.03 (0.98,1.09) 15,028 95.0 0.90 (0.81,1.01)
Married/Registered Partner 56,142 78.0 1.00 (reference) 1.00 (reference) 43,791 95.5 1.00 (reference)
Divorced/Separated/Widowed 14,459 78.8 1.05 (0.99,1.11) 1.01 (0.95,1.08) 11,387 95.0 0.90 (0.80,1.03)
Mother's education
None/Primary only 1215 83.3 1.35 (1.10,1.65) 1.76 (1.40,2.21) 1012 95.5 1.08 (0.73,1.60) 1.33 (0.86,2.03)
Lower secondary 15,878 77.9 0.96 (0.90,1.02) 1.08 (1.01,1.15) 12,376 94.9 0.95 (0.83,1.07) 0.98 (0.86,1.12)
Upper secondary & post-secondary non-tertiary 35,267 78.7 1.00 (reference) 1.00 (reference) 27,756 95.1 1.00 (reference) 1.00 (reference)
Undergraduate 30,043 78.2 0.97 (0.92,1.02) 0.88 (0.83,0.93) 23,484 95.7 1.15 (1.03,1.29) 1.12 (0.98,1.28)
Post-graduate 6538 76.6 0.89 (0.82,0.96) 0.75 (0.68,0.82) 5008 95.6 1.11 (0.91,1.34) 1.01 (0.81,1.26)
Mother's total income (NOK)
b200,000 9591 70.3 0.59 (0.55,0.63) 0.63 (0.58,0.68) 6743 94.8 0.89 (0.76,1.04) 0.96 (0.80,1.16)
200,000–349,999 29,012 77.2 0.84 (0.80,0.89) 0.84 (0.79,0.88) 22,408 95.2 0.97 (0.87,1.08) 0.99 (0.88,1.11)
350,000–499,999 33,790 80.1 1.00 (reference) 1.00 (reference) 27,062 95.4 1.00 (reference) 1.00 (reference)
500,000–699,999 12,654 81.2 1.07 (1.00,1.15) 1.11 (1.04,1.20) 10,269 95.3 0.98 (0.85,1.13) 1.00 (0.86,1.16)
N=700,000 4820 82.0 1.13 (1.02,1.25) 1.27 (1.14,1.42) 3950 96.5 1.32 (1.05,1.67) 1.39 (1.08,1.78)
Mother's occupational status
Employed: Managers/Professionals/Associates 34,698 79.7 1.04 (0.99,1.09) 1.04 (0.98,1.11) 27,661 95.7 1.13 (1.02,1.25) 1.05 (0.92,1.20)
Employed: Other 39,598 79.1 1.00 (reference) 1.00 (reference) 31,328 95.2 1.00 (reference) 1.00 (reference)
Unemployed 1251 77.1 0.89 (0.75,1.06) 0.98 (0.81,1.18) 965 94.2 0.82 (0.57,1.18) 0.84 (0.57,1.23)
Outside of workforced 14,256 73.2 0.72 (0.68,0.77) 0.81 (0.76,0.87) 10,441 94.8 0.92 (0.81,1.05) 0.98 (0.84,1.14)
Mother's country of birth
Norway 76,256 78.5 1.00 (reference) 1.00 (reference) 59,862 95.4 1.00 (reference)
Old EUe/EEA/EFTA, USA, Canada, Australia, NZ 3309 73.5 0.76 (0.69,0.84) 0.88 (0.78,0.98) 2433 95.2 0.95 (0.74,1.22)
Newer EU & other Europef 2752 77.8 0.96 (0.85,1.08) 1.04 (0.90,1.19) 2140 94.9 0.90 (0.69,1.16)
Africa 1793 72.2 0.71 (0.62,0.81) 0.76 (0.64,0.90) 1294 95.4 1.00 (0.71,1.41)
Asia 5104 82.5 1.29 (1.17,1.42) 1.44 (1.29,1.62) 4211 94.9 0.91 (0.75,1.10)
Central and South America 472 73.1 0.74 (0.57,0.97) 0.76 (0.57,1.02) 345 93.3 0.68 (0.39,1.19)
Number of children in mother's household
0 2147 80.3 1.08 (0.93,1.25) 1.20 (1.03,1.40) 1725 94.6 0.83 (0.62,1.10) 0.88 (0.65,1.18)
1 15,359 76.6 0.86 (0.82,0.92) 0.92 (0.87,0.98) 11,767 94.9 0.87 (0.77,0.99) 0.91 (0.80,1.04)
2 40,957 79.1 1.00 (reference) 1.00 (reference) 32,404 95.5 1.00 (reference) 1.00 (reference)
3 23,726 79.1 1.00 (0.95,1.06) 0.99 (0.93,1.04) 18,779 95.5 1.00 (0.89,1.12) 0.97 (0.87,1.09)
N=4 7368 75.1 0.79 (0.74,0.86) 0.80 (0.74,0.87) 5531 94.9 0.88 (0.74,1.05) 0.88 (0.73,1.06)
Mother's recent cervical screening history
Not attended screening in the past 4 years 18,390 75.5 0.83 (0.79,0.87) 0.86 (0.81,0.91) 13,890 94.8 0.88 (0.78,0.98) 0.94 (0.84,1.06)
Has attended in past 4 years, recent result normal 70,564 78.9 1.00 (reference) 1.00 (reference) 55,659 95.4 1.00 (reference) 1.00 (reference)
Has attended in past 4 years, recent result abnormal 1586 83.3 1.33 (1.12,1.59) 1.28 (1.07,1.53) 1321 95.4 0.99 (0.71,1.40) 1.08 (0.76,1.54)
Daughter received the combined MMR vaccine
Yes 85,901 80.1 1.00 (reference) 68,836 95.7 1.00 (reference)
No 4639 43.8 0.19 (0.18,0.21) 2034 82.9 0.22 (0.19,0.26)
Daughter's region of residence
East 43,118 78.4 1.00 (reference) 1.00 (reference) 33,813 94.8 1.00 (reference) 1.00 (reference)
South 5643 78.9 1.03 (0.94,1.13) 1.04 (0.95,1.15) 4454 96.4 1.48 (1.19,1.84) 1.49 (1.19,1.86)
West 20,074 78.7 1.02 (0.96,1.07) 0.99 (0.94,1.05) 15,799 95.5 1.17 (1.04,1.32) 1.17 (1.04,1.33)
Middle 12,726 76.1 0.88 (0.83,0.93) 0.85 (0.79,0.90) 9690 96.0 1.31 (1.13,1.52) 1.33 (1.14,1.55)
North 8969 79.3 1.05 (0.98,1.13) 1.02 (0.95,1.10) 7109 95.4 1.14 (0.98,1.34) 1.17 (0.99,1.37)
Daughter's year of birth
1997 30,420 72.0 1.00 (reference) 1.00 (reference) 21,895 96.4 1.00 (reference) 1.00 (reference)
1998 29,904 80.4 1.60 (1.52,1.68) 1.63 (1.55,1.71) 24,045 96.6 1.07 (0.94,1.22) 1.05 (0.92,1.21)
1999 30,216 82.5 1.84 (1.74,1.93) 1.86 (1.76,1.96) 24,930 93.0 0.50 (0.44,0.56) 0.48 (0.43,0.54)
a Logistic regression model estimates.
b Sample sizes refer to unadjusted models, and differ between variables due to missing values.
c Adjusted for all variables in the table except forMMRvaccination and variableswith all CIs overlapping unity in the unadjustedmodel (N initiation=87,705, N completion=68,974).
d Outside of workforce refers to those who are in education, retired or stay-at-home parents.
e Countries who joined the EU before 2004.
f Countries who joined the EU in 2004/2007 & European countries outside of EU/EEA/EFTA.
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Table 2
Crude rates of initiation of HPV vaccination among 12–13 year old girls in Norway
2009–2011 by parental country of birtha.
Mothers Fathers
Country N % vaccinated
(99% CI)
N % vaccinated
(99% CI)
Vietnam 500 90.6 (86.6,93.5) 460 90.2 (86.1,93.5)
Thailand 516 87.8 (83.5,91.1) 19 73.7 (41.8,93.8)
Kosovo 371 87.3 (82.1,91.2) 397 85.6 (80.6,89.8)
Afghanistan 318 85.8 (80.0,90.2) 291 88.7 (83.1,93.0)
Pakistan 810 84.3 (80.7,87.3) 869 81.7 (78.1,85.0)
Turkey 416 84.1 (78.9,88.2) 461 80.5 (75.3,85.0)
Iran 305 81.6 (75.2,86.7) 429 77.6 (72.0,82.6)
Iraq 646 81.1 (76.8,84.8) 646 81.4 (77.2,85.2)
Philippines 463 80.6 (75.4,84.9) 106 84.9 (73.9,92.6)
Poland 699 80.5 (76.4,84.1) 476 79.8 (74.7,84.4)
Sri Lanka 498 80.5 (75.5,84.7) 537 79.5 (74.7,83.8)
Sweden 886 79.1 (75.4,82.4) 761 76.0 (71.7,79.8)
Norway 76,322 78.5 (78.1,78.9) 74,745 78.5 (78.2,78.9)
Denmark 517 77.8 (72.7,82.1) 451 77.8 (72.4,82.7)
Bosnia-Herzegovina 261 75.1 (67.5,81.4) 265 75.1 (67.6,81.6)
US 431 74.9 (69.2,80.0) 423 70.4 (64.4,76.0)
Costa Rica 370 71.1 (64.6,76.8) 155 69.7 (59.3,78.8)
UK 254 69.7 (61.7,76.6) 406 76.6 (70.8,81.8)
Germany 395 65.1 (58.6,71.0) 397 76.1 (70.1,81.4)
Somalia 746 63.9 (59.3,68.3) 607 62.9 (57.7,67.9)
a The 20 most frequent countries of birth among mothers.
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each mother, we also used the Cytology registry to obtain individual informa-
tion on cervical screening attendance and result during the four years prior to
15 August of the scheduled year of HPV vaccination of the daughter. Norway
has an organized cervical screening programme which recommends screening
once every three years. The proportion of missing values per sociodemographic
variable retrieved from Statistics Norway ranged from 0.7% to 1.8% for mothers
and 1.4%–2.4% for fathers. Individuals with a missing value for any model vari-
able were excluded from that model, thus sample sizes differed according to
the variables included in each model.
Statistical analyses
To address correlates of vaccine uptake, we used logistic regression with
vaccination status as binary dependent variable, and report odds ratios (OR)
with 99% conﬁdence intervals (CI). HPV vaccine initiationwas deﬁned as having
received at least one dose of the vaccine. HPV vaccine completion was deﬁned
as having received all three recommended doses of the vaccine. Maternal and
paternal characteristics were addressed separately. Selection of independent
variables was guided by ﬁndings in previous studies (Fisher et al., 2013;
Kumar andWhynes, 2011; Spencer et al., 2013;Widgren et al., 2011).We report
bivariate (unadjusted) estimates for each independent variable. We also report
mutually adjusted multivariable estimates for independent variables with at
least one bivariate CI not overlapping unity. However, since correlates of MMR
and HPV vaccine uptake were similar, MMR vaccine status was not included
in multivariable models to avoid collinearity. Statistical computing was per-
formed with Stata MP version 13.1.
Results
Initiation of HPV vaccination
HPV vaccination was initiated by 78.2% of all girls included in the
study. The likelihood of vaccination decreased with increasingmaternal
age (Table 1). Girls with mothers older than age 50 at the time of their
daughter's scheduled vaccination had a particularly low likelihood of
initiation compared to girls with younger mothers (adjOR: 0.64, CI:
0.59, 0.71). Compared to girls with mothers of intermediate education
levels, HPV vaccine initiation was higher among girls whose mothers
had the lowest education, and lower for girls whose mothers had the
highest education (Table 1). In contrast, HPV vaccine initiation generally
increasedwith increasingmaternal income (Table 1). Compared to girls
with mothers of intermediate income, initiation was particularly low
among girls with mothers in the lowest income bracket (adjOR: 0.63,
CI: 0.58, 0.68). HPV vaccine initiation was lower among girls with
mothers who were outside the workforce compared to girls with
mothers who were currently employed (adjOR: 0.81, CI: 0.76, 0.87,
Table 1). Maternal marital status was not strongly associated with initi-
ation of HPV vaccination (Table 1).
There was considerable variation in HPV vaccine uptake by parental
country of birth. For instance, mothers from Vietnam had daughters
with an uptake exceeding ten percentage points of the population aver-
age, while mothers from Somalia and Germany had daughters with up-
take lower than ten percentage points below the population average
(Table 2). In the multivariable model, girls with mothers from Africa
had a somewhat lower likelihood of initiation (adjOR: 0.76, CI: 0.64,
0.90), and girls with mothers from Asia had a higher likelihood of initi-
ation (adjOR: 1.44, CI: 1.29, 1.62), compared to girls with Norwegian
mothers (Table 1). Compared with a two-child household, mothers
with four or more children, as well as mothers with a single child,
were somewhat less likely to have their daughters initiate HPV vaccina-
tion, while mothers with no children in their household had daughters
with a higher rate of initiation (Table 1). Mother's recent cervical
screening history was also associated with daughter initiation of HPV
vaccination. Compared with mothers who had a normal test at the last
screening visit, non-attendees had daughters with a lower likelihood
of initiating HPV vaccination, and mothers who had an abnormal test
at the last screening visit had daughters with a higher likelihood ofinitiating HPV vaccination (Table 1). In total, 94.8% of the girls received
the combined MMR vaccine. Girls who had not received the MMR
vaccine were far less likely to initiate HPV vaccination (OR: 0.19, CI:
0.18, 0.21, Table 1).
Region of residence was not a very strong predictor of HPV vaccine
initiation, although the uptake was somewhat lower in the middle
region compared to the other regions (Table 1). Initiation of HPV vacci-
nation was higher for girls born in 1998 and 1999 than for girls born in
1997 (Table 1).
The model estimates of the unadjusted and the adjusted models
differed somewhat more for the education variable than for the other
variables, indicating confounding. Since education and income were
moderately correlated (Spearman rs=0.43, p b 0.0001), we performed
additional multivariable models stratiﬁed by income level, which
showed that education was negatively associated with initiation in
each of the three lowest categories of income, but no association with
education was found in the two highest income categories (not
shown). We also performed a separate model for girls with mothers of
Norwegian descent, since they were poorly represented at the lowest
education level. This analysis conﬁrmed that, relative to the intermedi-
ate reference level, girlswith highly educated Norwegianmothers had a
signiﬁcantly lower likelihood of initiation of HPV vaccination. However,
no signiﬁcant differenceswere found for the two lowest levels of educa-
tion (not shown).
The analyses addressing associations between paternal characteris-
tics and initiation of HPV vaccination (Table 3) largely showed the
same patterns as described for the mother-daughter pairs (Table 1).
However, the differences observed were often somewhat smaller in
the paternal analyses. Moreover, occupational status was not signiﬁ-
cantly associated with daughter initiation of HPV vaccination in the pa-
ternal multivariable model.
Completion of HPV vaccination
Completion of all three recommended vaccine doses was achieved
for 74.6% of all girls included in the study, and for 69.4, 77.6, and 76.7%
of the 1997, 1998 and 1999 cohorts, respectively. Among girls who ini-
tiated HPV vaccination, 95.3% completed the vaccine series.
Among girls who initiated HPV vaccination, therewas little variation
in completion across the categories of each included characteristic.
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the models addressing maternal (Table 1) and paternal characteristics
(Table 3) generally showed similar results. However, if the girl had
not received the MMR vaccine, her likelihood of completion was con-
siderably lower than if she had received the vaccine. Moreover, theTable 3
Odds ratiosa for initiation and completion of routine HPV vaccination among 12–13 year old g
Initiation
Nb % initiated Unadjusted OR
(99% CI)
Father's age
b35 3344 80.0 1.05 (0.94,1.19
35–39 16,810 80.0 1.06 (1.00,1.13
40–44 31,070 79.1 1.00 (reference
45–49 22,678 78.1 0.94 (0.89,0.99
N=50 14,663 74.3 0.76 (0.72,0.81
Father's marital status
Unmarried 17,818 79.3 1.09 (1.04,1.15
Married/registered partner 55,695 77.8 1.00 (reference
Divorced/separated/widowed 13,223 79.1 1.08 (1.01,1.15
Father's education
None/primary only 746 82.3 1.24 (0.96,1.59
Lower secondary 16,448 78.7 0.98 (0.93,1.04
Upper secondary & post-secondary non-tertiary 42,001 79.0 1.00 (reference
Undergraduate 18,921 76.9 0.89 (0.84,0.94
Post-graduate 9236 77.0 0.89 (0.83,0.96
Father's total income (NOK)
b200,000 4329 72.6 0.73 (0.66,0.80
200,000–349,999 12,301 77.5 0.94 (0.88,1.01
350,000–499,999 27,032 78.5 1.00 (reference
500,000–699,999 22,598 79.3 1.05 (0.99,1.11
N=700,000 20,589 78.8 1.02 (0.96,1.08
Father's occupational status
Employed: managers/professionals/associates 34,906 78.4 0.98 (0.94,1.03
Employed: other 41,889 78.7 1.00 (reference
Unemployed 1225 77.8 0.95 (0.79,1.13
Outside of workforced 8707 76.2 0.86 (0.80,0.93
Father's country of birth
Norway 74,745 78.5 1.00 (reference
Old EUe/EEA/EFTA, USA, Canada, Australia, NZ 3316 73.8 0.77 (0.69,0.85
Newer EU & Other Europef 2165 78.2 0.98 (0.85,1.12
Africa 1662 71.6 0.69 (0.60,0.79
Asia 4170 81.4 1.19 (1.08,1.33
Central and South America 339 72.6 0.72 (0.53,0.99
Number of children in father's household
0 13,101 77.4 0.89 (0.84,0.95
1 12,976 77.3 0.89 (0.84,0.95
2 34,301 79.3 1.00 (reference
3 20,273 79.1 0.99 (0.94,1.05
N=4 6086 74.7 0.77 (0.71,0.84
Daughter received the combined MMR vaccine
Yes 84,240 80.1 1.00 (reference
No 4325 43.3 0.19 (0.18,0.21
Daughter's region of residence
East 42,126 78.4 1.00 (reference
South 5520 78.9 1.03 (0.94,1.13
West 19,628 78.6 1.01 (0.96,1.07
Middle 12,511 76.1 0.88 (0.82,0.93
North 8770 79.4 1.06 (0.99,1.14
Daughter's year of birth
1997 29,788 71.9 1.00 (reference
1998 29,242 80.4 1.60 (1.52,1.69
1999 29,535 82.6 1.85 (1.76,1.95
a Logistic regression model estimates.
b Sample sizes refer to unadjusted models, and differ between variables due to missing valu
c Adjusted for all variables in the table except forMMRvaccination and variableswith all CIs o
d Outside of workforce refers to those who are in education, retired or stay-at-home parent
e Countries who joined the EU before 2004.
f Countries who joined the EU in 2004/2007 & European countries outside of EU/EEA/EFTA.completion rates were slightly lower in the eastern region as compared
to the other regions of Norway, and lower in 1999 than in the two pre-
ceding years. A higher completion rate was observed for the highest
level ofmaternal income (Table 1), and a lower completion ratewas ob-
served for the lowest level of paternal income (Table 3).irls in Norway 2009–2011 by father and daughter characteristics.
Completion among initiators
AdjustedcOR
(99% CI)
Nb % completed Unadjusted OR
(99% CI)
AdjustedcOR
(99% CI)
) 1.08 (0.95,1.22) 2675 95.1 0.95 (0.74,1.21)
) 1.09 (1.02,1.16) 13,456 95.2 0.98 (0.86,1.11)
) 1.00 (reference) 24,584 95.3 1.00 (reference)
) 0.93 (0.88,0.98) 17,703 95.6 1.06 (0.94,1.20)
) 0.77 (0.72,0.82) 10,888 95.3 0.99 (0.86,1.13)
) 1.11 (1.04,1.18) 14,135 94.9 0.87 (0.78,0.98) 0.93 (0.82,1.06)
) 1.00 (reference) 43,349 95.5 1.00 (reference) 1.00 (reference)
) 1.22 (1.13,1.31) 10,459 95.1 0.91 (0.80,1.04) 1.03 (0.88,1.21)
) 1.41 (1.07,1.86) 614 96.4 1.34 (0.77,2.36)
) 1.02 (0.96,1.09) 12,950 95.0 0.95 (0.84,1.07)
) 1.00 (reference) 33,177 95.2 1.00 (reference)
) 0.90 (0.84,0.95) 14,556 95.6 1.09 (0.96,1.23)
) 0.91 (0.84,0.99) 7114 95.8 1.14 (0.96,1.34)
) 0.78 (0.69,0.87) 3143 93.7 0.72 (0.58,0.88) 0.76 (0.60,0.96)
) 0.95 (0.88,1.03) 9528 94.9 0.89 (0.77,1.03) 0.92 (0.79,1.08)
) 1.00 (reference) 21,214 95.4 1.00 (reference) 1.00 (reference)
) 1.04 (0.98,1.10) 17,916 95.6 1.04 (0.92,1.18) 1.06 (0.93,1.21)
) 1.04 (0.98,1.11) 16,230 95.7 1.06 (0.93,1.21) 1.08 (0.94,1.25)
) 1.00 (0.94,1.05) 27,381 95.6 1.08 (0.97,1.19) 1.06 (0.95,1.18)
) 1.00 (reference) 32,982 95.3 1.00 (reference) 1.00 (reference)
) 1.04 (0.86,1.26) 953 95.0 0.93 (0.63,1.36) 1.07 (0.71,1.59)
) 0.96 (0.89,1.05) 6635 94.4 0.83 (0.72,0.97) 1.00 (0.84,1.20)
) 1.00 (reference) 58,706 95.3 1.00 (reference)
) 0.83 (0.74,0.93) 2447 95.3 0.98 (0.76,1.26)
) 1.00 (0.86,1.17) 1692 95.8 1.12 (0.81,1.53)
) 0.77 (0.66,0.90) 1190 95.7 1.09 (0.75,1.58)
) 1.31 (1.16,1.47) 3394 95.2 0.97 (0.79,1.21)
) 0.77 (0.55,1.07) 246 94.3 0.81 (0.40,1.65)
) 0.83 (0.77,0.90) 10,137 94.5 0.77 (0.68,0.89) 0.82 (0.69,0.96)
) 0.88 (0.82,0.94) 10,034 95.3 0.92 (0.79,1.06) 0.93 (0.80,1.07)
) 1.00 (reference) 27,187 95.7 1.00 (reference) 1.00 (reference)
) 0.98 (0.93,1.04) 16,041 95.6 0.98 (0.87,1.12) 0.96 (0.85,1.09)
) 0.76 (0.70,0.83) 4545 94.9 0.84 (0.69,1.01) 0.83 (0.68,1.00)
) 67,435 95.7 1.00 (reference)
) 1871 83.1 0.22 (0.19,0.26)
) 1.00 (reference) 33,034 94.9 1.00 (reference) 1.00 (reference)
) 1.01 (0.92,1.11) 4357 96.4 1.46 (1.17,1.83) 1.46 (1.17,1.82)
) 0.98 (0.93,1.04) 15,426 95.5 1.16 (1.03,1.31) 1.14 (1.01,1.29)
) 0.84 (0.79,0.90) 9519 96.0 1.30 (1.12,1.50) 1.32 (1.13,1.54)
) 1.06 (0.98,1.15) 6965 95.5 1.14 (0.97,1.34) 1.16 (0.99,1.37)
) 1.00 (reference) 21,414 96.5 1.00 (reference) 1.00 (reference)
) 1.62 (1.54,1.71) 23,508 96.7 1.06 (0.93,1.22) 1.05 (0.92,1.20)
) 1.88 (1.78,1.98) 24,384 93.0 0.49 (0.44,0.55) 0.48 (0.43,0.54)
es.
verlapping unity in the unadjustedmodel (N initiation=85,039, N completion=67,762).
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This study shows that publicly funded school-based vaccination gen-
erally provides equitable HPV vaccine uptake. However, some dispar-
ities in initiation of HPV vaccination were found. The lowest rates and
likelihoods of initiation were identiﬁed among girls who had not re-
ceived theMMRvaccine, girls withmothers in the lowest incomebrack-
et, and girlswithmothers age 50 or above. Girlswith parents originating
from a subset of foreign countries, and girls with mothers who were
outside the workforce also had a relatively low uptake.
A recentmeta-analysis did notﬁnd strong evidence for differences in
HPV vaccination initiation by parental educationor income (Fisher et al.,
2013). We found opposing effects of parental education and income,
which may be explained by the moderate correlation documented be-
tween these two variables. In Norway, dispersion in earnings is remark-
ably low (Haegeland et al., 1999), and the economic returns of higher
education are far lower than commonly observed in other countries
(OECD, 2014; Reisel, 2013). However, the estimates of the education
variable changed markedly with multivariable modelling, implying
that education was particularly inﬂuenced by other variables that also
were associated with vaccine uptake. Further, the effect of education
was not consistent across all levels of income. The most striking effect
of parental education was not a particularly low uptake at any level of
education, but a high uptake at the lowest level of education. In contrast,
initiation of HPV vaccinationwas particularly low in the lowest parental
income bracket, which affected many girls. Hence, from a public health
perspective, parental income appeared to be a more important predic-
tor of inequality than did parental education.
We conﬁrm previous ﬁndings that maternal cervical screening
attendance, as well as experience with an abnormal screening result,
may inﬂuence daughter HPV vaccine uptake (Chao et al., 2009; Spencer
et al., 2013). This indicates thatmaternal knowledge about cervical cancer
and/ormaternal compliance to preventive public healthmeasures in gen-
eralmay be relevant for daughter uptake of theHPVvaccine.We also con-
ﬁrm (Ogilvie et al., 2010) that having more than three children in the
household may reduce the likelihood of HPV vaccine uptake. However,
in contrast to some other studies (Sinka et al., 2014; Smith et al., 2011),
we did not ﬁnd strong evidence of socioeconomic disparities in comple-
tion of HPV vaccination.
A family model of two workers/caregivers who share paid and un-
paid work equally, is a political goal in many countries. In Norway, the
involvement of fathers in daily child care has become substantial
(Kitterod and Lappegard, 2012), which may facilitate comparatively
more paternal involvement in child health-related decision making
(Zvara et al., 2013). Although the associations to HPV vaccine uptake
sometimes were slightly weaker in the paternal than in the maternal
models in the present study, the patterns were similar, indicating that
maternal and paternal sociodemographic characteristics play a similar
role for daughter HPV vaccine uptake. Hence, efforts to decrease dispar-
ities in HPV vaccine uptake, and to increase the uptake in general,
should reach and appeal to mothers and fathers alike. Further studies
on father involvement in decisions regarding child HPV vaccine uptake
are needed.
Study limitations and strengths
The present study has several strengths that set it apart from studies
on HPV vaccine uptake performed in a similar setting in other countries
(Fisher et al., 2014; Kumar andWhynes, 2011; Ogilvie et al., 2010; Sinka
et al., 2014; Smith et al., 2011;Widgren et al., 2011).We investigate var-
iables registered at the individual level, and all dynamic variables refer
to the year of scheduled vaccination. Furthermore, we present data on
maternal and paternal characteristics separately, which to our knowl-
edge has not been done before. Another strength of this study is the
use of administrative and health registry data that is not self-reported,
close to complete and of high validity for the entire population ofNorwegian girls eligible for vaccination, and for their parents. The regis-
tries used in this study are continuously updated and have standardized
routines for retrieval and registration of data, ensuring high data quality
(Larsen et al., 2009; Seaboe et al., 2003; Trogstad et al., 2012). The use of
population-based registry data in the present study minimizes the po-
tential for selection, misclassiﬁcation and response bias. However, the
analyses presented here do not address causal relationships or identify
individual barriers toHPVvaccine uptake inNorway. A rangeof individual
barriers to HPV vaccination, such as receiving inadequate information,
perceiving the daughter as too young for the vaccine, and concerns
about side effects, have previously been identiﬁed in surveys and qualita-
tive studies (Grandahl et al., 2014; Marlow et al., 2007; Waller et al.,
2006). Further studies are needed to address how the population-level
characteristics addressed heremay be associated to individual choices re-
garding HPV vaccination.
Themultivariable models presented include many variables, several
of which are correlated, which could introduce overadjustment bias and
affect model precision (Schisterman et al., 2009). It is also possible that
we did not adjust for all salient confounders (i.e. residual confounding).
Moreover, there are likely to be associations between the variables in
this comprehensive dataset that were not fully addressed in themodels.
As such, assessments of the public health relevance of the data present-
ed here should be based on the crude estimates as well as the adjusted
estimates. In general, the patterns observed in the crude point and inter-
val estimates of this study were also observed in the corresponding ad-
justed estimates.Conclusions
Knowledge from this study may be relevant for other vaccination
programmes, and may be useful for the development of strategies to
further improve uptake of the HPV vaccine. Although this study shows
that alarming disparities in the uptake of the HPV vaccinewithin a pub-
licly funded school-based delivery system do not exist, some sub-
groups had a relatively low uptake and contained many girls. Informa-
tion campaigns designed to reach these groups could improve equity
in delivery. Moreover, since the uptake was far lower for the HPV than
for the MMR vaccine across all sub-groups investigated, this study
also demonstrates a large general potential for improving HPV vac-
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